Search

Your search keyword '"Joniau, S"' showing total 82 results

Search Constraints

Start Over You searched for: Author "Joniau, S" Remove constraint Author: "Joniau, S" Database OAIster Remove constraint Database: OAIster
82 results on '"Joniau, S"'

Search Results

1. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.

2. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.

3. Radikale Prostatektomie (RP) oder Radiotherapie (RT) beim metastasierten, hormonnaiven Prostatakarzinom (PCA) mit geringer Metastasenlast: Ein indirekter Vergleich mit der STAMPEDE Studie, Arm H

4. Radikale Prostatektomie (RP) oder Radiotherapie (RT) beim metastasierten, hormonnaiven Prostatakarzinom (PCA) mit geringer Metastasenlast: Ein indirekter Vergleich mit der STAMPEDE Studie, Arm H

5. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

6. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer

7. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

8. Optimal (68)Ga-PSMA and (18)F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer

9. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (Nature Genetics, (2021), 53, 1, (65-75), 10.1038/s41588-020-00748-0).

10. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

11. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (Nature Genetics, (2021), 53, 1, (65-75), 10.1038/s41588-020-00748-0).

12. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

13. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

14. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients.

15. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

16. Optimal (68)Ga-PSMA and (18)F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer

17. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

18. Optimal (68)Ga-PSMA and (18)F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer

19. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

20. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

21. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

22. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

23. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

24. Correction to: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8).

25. Germline variation at 8q24 and prostate cancer risk in men of European ancestry.

26. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1).

27. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8).

28. Correction to: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8).

29. Germline variation at 8q24 and prostate cancer risk in men of European ancestry.

30. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1).

31. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8).

32. Germline variation at 8q24 and prostate cancer risk in men of European ancestry (vol 9, 4616, 2018)

33. Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay.

34. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

35. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG : not as bad as previously thought

37. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

38. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

39. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

40. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

41. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought

42. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

44. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought

45. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought

47. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

48. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.

49. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

50. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy?

Catalog

Books, media, physical & digital resources